While some companies are focused on growth for the next quarter or next year, Cubist Pharmaceuticals (CBST) is thinking long term. In June, the Lexington,Mass.-based drugmaker outlined an ambitious five-year plan for future growth. By 2017, Cubist expects revenue to hit $2 billion. The company did $754 million in sales last year. Almost all of that came from Cubincin, which is used to treat blood and skin infections. Cubist plans to hit its